Surveillance for hepatocellular carcinoma: How can we do better?

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death worldwide and one of the most common causes of death in patients with cirrhosis. Although it has a lower incidence in the United States than other countries, its incidence is dramatically on the rise. HCC surveillance is recommended at regular intervals in patients with cirrhosis to detect tumors at an early stage, when curative options exist. Ultrasound and alpha-fetoprotein remain the surveillance tests of choice and should be used in combination every 6 months until better surveillance tools become available. Unfortunately, HCC surveillance continues to be underutilized in clinical practice, with less than 20% of at-risk patients undergoing surveillance. This is related to multiple causes, including underrecognition of liver disease and cirrhosis in approximately 40% of patients; however, the most common reason is a failure to order surveillance in those with known cirrhosis.

Original languageEnglish (US)
Pages (from-to)308-313
Number of pages6
JournalAmerican Journal of the Medical Sciences
Volume346
Issue number4
DOIs
StatePublished - Oct 2013

Fingerprint

Hepatocellular Carcinoma
Fibrosis
Incidence
alpha-Fetoproteins
Liver Cirrhosis
Liver Diseases
Cause of Death
Neoplasms

Keywords

  • Liver cancer
  • Quality of care
  • Screening
  • Underutilization

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Surveillance for hepatocellular carcinoma : How can we do better? / Hassett, Molly; Yopp, Adam C.; Singal, Amit G.

In: American Journal of the Medical Sciences, Vol. 346, No. 4, 10.2013, p. 308-313.

Research output: Contribution to journalArticle

@article{46dbb5054f4244f2bc712ee0e4c5b204,
title = "Surveillance for hepatocellular carcinoma: How can we do better?",
abstract = "Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death worldwide and one of the most common causes of death in patients with cirrhosis. Although it has a lower incidence in the United States than other countries, its incidence is dramatically on the rise. HCC surveillance is recommended at regular intervals in patients with cirrhosis to detect tumors at an early stage, when curative options exist. Ultrasound and alpha-fetoprotein remain the surveillance tests of choice and should be used in combination every 6 months until better surveillance tools become available. Unfortunately, HCC surveillance continues to be underutilized in clinical practice, with less than 20{\%} of at-risk patients undergoing surveillance. This is related to multiple causes, including underrecognition of liver disease and cirrhosis in approximately 40{\%} of patients; however, the most common reason is a failure to order surveillance in those with known cirrhosis.",
keywords = "Liver cancer, Quality of care, Screening, Underutilization",
author = "Molly Hassett and Yopp, {Adam C.} and Singal, {Amit G.}",
year = "2013",
month = "10",
doi = "10.1097/MAJ.0b013e31828318ff",
language = "English (US)",
volume = "346",
pages = "308--313",
journal = "The American journal of the medical sciences",
issn = "0002-9629",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Surveillance for hepatocellular carcinoma

T2 - How can we do better?

AU - Hassett, Molly

AU - Yopp, Adam C.

AU - Singal, Amit G.

PY - 2013/10

Y1 - 2013/10

N2 - Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death worldwide and one of the most common causes of death in patients with cirrhosis. Although it has a lower incidence in the United States than other countries, its incidence is dramatically on the rise. HCC surveillance is recommended at regular intervals in patients with cirrhosis to detect tumors at an early stage, when curative options exist. Ultrasound and alpha-fetoprotein remain the surveillance tests of choice and should be used in combination every 6 months until better surveillance tools become available. Unfortunately, HCC surveillance continues to be underutilized in clinical practice, with less than 20% of at-risk patients undergoing surveillance. This is related to multiple causes, including underrecognition of liver disease and cirrhosis in approximately 40% of patients; however, the most common reason is a failure to order surveillance in those with known cirrhosis.

AB - Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death worldwide and one of the most common causes of death in patients with cirrhosis. Although it has a lower incidence in the United States than other countries, its incidence is dramatically on the rise. HCC surveillance is recommended at regular intervals in patients with cirrhosis to detect tumors at an early stage, when curative options exist. Ultrasound and alpha-fetoprotein remain the surveillance tests of choice and should be used in combination every 6 months until better surveillance tools become available. Unfortunately, HCC surveillance continues to be underutilized in clinical practice, with less than 20% of at-risk patients undergoing surveillance. This is related to multiple causes, including underrecognition of liver disease and cirrhosis in approximately 40% of patients; however, the most common reason is a failure to order surveillance in those with known cirrhosis.

KW - Liver cancer

KW - Quality of care

KW - Screening

KW - Underutilization

UR - http://www.scopus.com/inward/record.url?scp=84885019607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885019607&partnerID=8YFLogxK

U2 - 10.1097/MAJ.0b013e31828318ff

DO - 10.1097/MAJ.0b013e31828318ff

M3 - Article

C2 - 23426089

AN - SCOPUS:84885019607

VL - 346

SP - 308

EP - 313

JO - The American journal of the medical sciences

JF - The American journal of the medical sciences

SN - 0002-9629

IS - 4

ER -